European Journal of Molecular & Clinical Medicine

Abstract

Background:
Aesthetically, warts affect on face and hands duo to great discomfort to the patient. The common treatment methods cause pigmentary changes and scarring. Moreover, recurrence of infection. Because bleomycin is considered an anti-tumor agent, this project is considered a pioneering study in Iraq to evaluate the efficacy of bleomycin intralesional in treating intractable warts.
Patient and Methods:
A total of 23 patients with (104) rebellious warts were treated with intralesional bleomycin. The response to treatment was followed after 2 weeks, 1 month and 3 months. The follow-up method was calculated by a special recording system (no response = 0), (response = 1) and (complete recovery = 2).
Results:
Results showed at 2 weeks follow up (13.1%) of the palmoplantar, (19.4%) of the periungual and (25%) of the other sites warts improved to score 1. After 1 month the score 1 response for palmoplantar, periungual and other sites warts were (39.2%), (41.9%) and (25%) respectively, while the score 2 response for palmoplantar, periungual and other sites warts were (30.4%), (32.3%) and (75%) respectively. After three month, reaction in periungual and other sites warts is 100%, whereas in palmoplantar warts were 94.2% with a total response rate of 96.1 % according to the scoring system.
Conclusion:
Our findings suggest that Bleomycin is significantly effective in the medication for insurgent warts. It's safe and free of side effects apart from minimal local pain with no recurrence rate of warts after bleomycin treatment.